Our intention was to examine if subnormal testosterone levels in older men were associated with a reduction in quality of life and physical and mental health, and secondly to examine if testosterone treatment could improve these conditions. We performed a nested case-control study and a 1-year testosterone intervention study. Men with subnormal testosterone had significantly higher weight, fat mass and abdominal adipose tissue. They also had significantly higher glucose and insulin levels, and they had higher triglyceride levels. Testosterone treatment had a large impact on body composition with reduced fat mass and abdominal adipose tissue and increased fat-free mass, but it did not affect weight and glucose and lipid metabolism. Bone mineral density in the hip was significantly higher after the testosterone treatment. Older men with subnormal testosterone levels had an unfavorable metabolic profile. Testosterone treatment improved body composition, but it did not reverse the unfavorable metabolic profile.
Introduction
It is generally accepted that testosterone levels decrease with age, as shown by several large population-based cross-sectional and longitudinal studies. [1] [2] [3] [4] The decrease in testosterone levels during aging is, however, characterized by a high inter-individual variability. 2 Some of the age-related changes in muscle and fat mass, bone mineral density (BMD) and sexual and cognitive functions resemble those observed in young testosteronedeficient men. These similarities suggest that testosterone treatment in partially androgen-deficient older men may prevent or reverse the effect of aging, and consequently, testosterone supplementation in elderly men has increased rapidly in the last few years. 5 However, placebo-controlled trials in older men with low or subnormal testosterone levels have yielded inconsistent results. 6 Thus, whether androgen therapy can make a significant, objective improvement in meaningful health outcomes and without any serious side effects is still uncertain.
The participants in previous testosterone treatment studies have mainly been recruited by advertisement or by direct mailing, and so far no study has been published on men recruited from a general population. In the fifth Tromsø survey in 2001, total testosterone was measured in 3447 men, providing an opportunity to invite elderly men (60-80 years) with subnormal testosterone levels to participate in both a nested case-control study and a testosterone intervention study. Our intention was to examine whether subnormal testosterone levels in elderly men were associated with a reduced quality of life (QoL), physical and mental health, and, furthermore, to examine whether testosterone treatment could improve these conditions.
Subjects and methods
The Tromsø study is an ongoing general health survey performed for the fifth time in 2001 in a manner similar to the previous ones. 7 All men and women 30 years and older, living in the municipality of Tromsø and who had participated in the second phase of the fourth Tromsø study in 1994/ 1995 2 or became 30, 40, 45, 60 or 75 years old during 2001, were invited to participate. Non-fasting blood samples were drawn and analyzed for serum testosterone.
In 2005, all men aged 60-80 years with a serum testosterone level p11.0 nmol/l in the survey in 2001 were invited to a follow-up examination at the Clinical Research Unit, University Hospital of North Norway. For each subject with serum testosterone p11.0 nmol/l, a randomly selected agedmatched control subject from the same survey with serum testosterone above 11.0 nmol/l was also invited. The invitation letter informed about the purpose of the study, but did not disclose the subject's testosterone level. Among the 3447 men with serum testosterone measurements in the fifth Tromsø study in 2001, 335 men aged between 60 and 80 years in 2005 had a serum total testosterone level p11.0 nmol/l, and were invited to the follow-up study. Among these, 157 attended, and 69 men still had total testosterone levels p11.0 nmol/l. The majority of the men had testosterone levels between 6.0 and 11.0, and they are therefore referred to as having subnormal testosterone levels. As agematched controls, 335 subjects with serum testosterone levels 411.0 nmol/l in the fifth Tromsø study were invited. Among the 124 who attended, 104 still had a total testosterone in the normal range, 411.0 nmol/l.
At the follow-up visit, blood was drawn in the non-fasting state between 0800 and 1100 hours, and serum samples were analyzed for serum testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone-binding globulin (SHBG) and prostate-specific antigen (PSA). A general examination including a digital rectal examination of the prostate was also performed. Those who still had serum testosterone levels in the same range (above or below 11.0 nmol/l) were informed that their testosterone levels were similar to that at the fifth Tromsø study and invited to additional examinations. Those consenting returned on a separate day to the Clinical Research Unit for more extensive investigations. Fasting blood samples including screening for prolactin and thyroid stimulating hormone were drawn at 0800 hours and an oral glucose tolerance test (OGTT) with ingestion of 75 g glucose was performed. Homeostatic model assessment was used to calculate the insulin resistance (HOMA IR ) (fasting insulin, mU/ml Â fasting plasma glucose, mmol/l)C22.5). 8 Height, weight and waist circumference (WC) were measured in subjects wearing light clothing without shoes. Body mass index (BMI) was calculated (kg/m 2 ). BMD of the lumbar spine and hip together with fat-free mass (FFM) and fat mass (FM) were determined by dual-energy X-ray absorptiometry (DEXA) using the Lunar Prodigy instrument (Lunar Radiation Corp., Madison, WI, USA). The extent of the abdominal adipose tissue was estimated in a computed tomography (CT) scan with an abdominal slice at the level of the intervertebral space between the second and third lumbar vertebrae using a Siemens Sensation 16 CT scanner (Siemens AG, Munich, Germany). The amount of adipose tissue was calculated by using the volume application of the scanner, using evaluation limits between À40 and À140 Hounsfield units in a 10 mm thick slice. An experienced radiologist (TS), who was blinded to the testosterone levels of the men, examined all the CT scans and calculated the visceral abdominal tissue (VAT), subcutaneous abdominal tissue (SAT) and total abdominal adipose tissue (TAT). A manual outline of the skin surface was first used to calculate the fat content of the entire body slice, TAT. Thereafter, an outline of the peritoneum was drawn manually on the CT slice for calculations of VAT and SAT. Gait and balance were evaluated by three functional tests: standing balance, fast walk and chair rise. 9 Muscle strength was examined by knee extension of the dominant leg (peak torque, N m) using a NORM dynamometer (CSMI, Norwood, MA, USA) and by handgrip strength (kPa) on both the dominant and non-dominant hand using a Martin vigorimeter (Elmed Inc., Addison, IL, USA). To assess physical activity, the short form of the International Physical Activity Questionnaire, IPAQ, was used. Using this questionnaire, a measure of physical activity can be obtained in MET minutes where MET is multiples of the resting metabolic rate. 10 A series of neuropsychological tests for cognitive and emotional function was performed. 11 We also used the Aging Male's Symptoms Scale (AMS) 12 and the World Health Organization quality of life old score (WHOQOL-OLD). 13 The examiners, who were nurses, were extensively trained and certified by a clinical neuropsychologist (KW), carried out the tests in a standardized fashion and in identical order. They were blinded to the testosterone status of the participants.
The subjects were then informed about their testosterone levels. Those with total testosterone p11.0 nmol/l were invited to a 1-year (52 weeks) intervention study. Exclusion criteria were prostate cancer or other malignancies, unstable ischemic or congestive heart disease, epilepsy, migraine, hematocrit450% or hemoglobin417.0 g per 100 ml, PSA44.0 mg/l, creatinine4130 mmol/l, alanine aminotransferase4100 U/l, known allergic reaction to the study medication, current treatment with warfarin, or participation in other studies. Those consenting were randomly allocated in a double-blind fashion to receive either testosterone treatment with an intramuscular depot injection of testosterone (testosterone undecanoate 1000 mg, Nebido, Bayer Schering Pharma AG, Berlin, Older men and testosterone J Svartberg et al Germany) or identically looking placebo (placebo for testosterone undecanoate, Bayer Schering Pharma AG, Germany). Each participant received a total of five injections, at baseline, and after 6, 16, 28 and 40 weeks. The injections were given by study nurses ensuring 100% compliance to the study medication. After 52 weeks, the initial examinations and tests were repeated.
Sex hormone analyses and biochemistry Serum total testosterone, FSH, LH, estradiol and PSA were analyzed by electrochemical luminescence immunoassay (ECLIA) using an automated clinical chemistry analyzer (Modular E, Roche Diagnostics GmbH, Mannheim, Germany). The total analytical precision expressed as the sum of intraand interassay coefficients of variation (CV a ) were 5.6, 4.0, 2.2, 4.7 and 3.2%, and the reference ranges were 10-28 nmol/l, o12 IU/l, o9 IU/l, o0.20 nmol/l and o4.0 mg/l, respectively. Serum SHBG, insulin and C-peptide were analyzed by immunometry based on chemiluminescence using an automated clinical chemistry analyzer (Immulite 2000, Diagnostic Product Corp., Los Angeles, CA, USA). The CV a s were 5.2, 8.8 and 7.3%, respectively. Plasma glucose was measured by an enzymatic colorimetric assay using an automated clinical chemistry analyzer (Modular P, Roche Diagnostics GmbH, Mannheim, Germany). Similarly, serum cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides were measured using Modular P. The CV a s were 2.7, 2.7, 2.0, 2.3 and 2.4%, respectively. Glycosylated hemoglobin (HbA 1c ) was measured by high-performance liquid chromatography (HPLC) using a Variant II (Bio-Rad Laboratories, Hercules, CA, USA). The analysis, certified by the Norwegian glycohemoglobin standardization program, had a CV a o3.0%.
Free testosterone was calculated from total testosterone and SHBG using a fixed albumin value. 14 
Statistical analyses
The non-parametric Mann-Whitney U-test was used to determine the differences between the groups. Delta values, defined as baseline value minus the value at the end of the intervention, were used. All tests were done two-sided, and Po0.05 was considered statistically significant. Values are expressed as mean and s.d., if nothing else is noted. Statistical analyses were performed with SPSS version 12.1 (SPSS Inc., Chicago, IL).
Ethics
The study was approved by the Tromsø Regional Research Ethics Committee, and all participants gave written informed consent to participate.
Results
The nested case-control study Among the 3447 men with serum testosterone measurements in the fifth Tromsø study in 2001, 335 men aged between 60 and 80 years in 2005 had a serum total testosterone level p11.0 nmol/l, and were invited to the follow-up study. Among these, 157 attended, and 69 men still had total testosterone levels p11.0 nmol/l. The majority of the men had testosterone levels between 6.0 and 11.0, and they were therefore referred to as having subnormal testosterone levels. As age-matched controls, 335 subjects with serum testosterone levels411.0 nmol/l in the fifth Tromsø study were invited. Among the 124 who attended, 104 still had a total testosterone in the normal range,411.0 nmol/l.
The characteristics of the subjects in the nested case-control study are shown in Table 1 . The mean age was 69 years in both the groups, whereas men with subnormal testosterone levels had significantly higher weight (92.6 vs 81.9 kg), higher BMI (30.1 vs 26.5 kg/m 2 ) and larger WC (107 vs 97 cm) (all Po0.001). Approximately 20% of the men in each group smoked. Coronary heart disease (CHD), type-2 diabetes and hypertension were more common in men with subnormal testosterone levels. There was no difference in PSA levels between the two groups.
Body composition. As assessed by DEXA, there was no difference in FFM between the two groups, but the total FM percentage was significantly higher in the subnormal testosterone group (32.2 vs 25.9%; Po0.001). CT scans of the abdomen showed that men in the subnormal testosterone group had significantly higher VAT, SAT and TAT (all Po0.001) compared with the controls (Table 1) .
Muscle strength, physical function and bone mineral density. Muscle strength did not differ significantly between the two groups. However, men in the control group performed significantly better in two of the three functional tests and had a nonsignificantly higher IPAQ score. BMD in both the lumbar spine and the hip showed no statistically significant difference (Table 2) .
Glucose metabolism and lipids. At the OGTT, men with subnormal testosterone levels had significantly higher fasting and 2-h glucose levels compared with the control group. Likewise, the HbA 1c , insulin, C-peptide and triglycerides levels and the HOMA IR values were significantly higher in men with subnormal testosterone levels (Table 3) .
QoL, emotional and cognitive function. Men in the control group had significantly better results in the total score and in the somatic domain of the AMS, whereas the results in the sexual domain of the AMS Older men and testosterone J Svartberg et al
were not significantly different. In the Beck Depression Inventory (BDI), men in the control group scored significantly better in the second subscale and had also a significantly better total score (Table 4 ). There were no differences between the groups in the General Health Questionnaire (GHQ) and the WHOQOL-OLD (data not shown). In 10 of the 12 cognitive function tests, men from the control group had a more favorable result, but the difference was only significant in the Trail Making Test B, which is the most demanding and complex test (Table 5 ). The composite cognitive score was also more favorable in the control group, but again the difference was not significant ( Table 5 ).
The intervention study Thirty-one men were excluded from participation mainly due to a PSA level above the reference range (44.0 mg/l) (no. 18) or the use of warfarin (no. 6).
Nineteen men were included in the testosterone treatment group and nineteen men in the placebo group. One participant from each group withdrew from the study without stating reason, and one participant in the treatment group died from cardiac arrhythmia, which was not considered related to the testosterone therapy. Thus, 35 men completed the intervention study. All comparisons between the two treatment groups are based on delta values (baseline value minus value at end of intervention).
As expected, total and free testosterone levels increased significantly in the treatment group, and total testosterone reached a stable level after the second injection as shown in Figure 1 . Estradiol did not increase during testosterone treatment, but as estradiol decreased in the placebo group a significant difference between the groups was found at the end of the study (Table 1) . LH and FSH levels decreased in the testosterone group, and at the end of the study both the LH and the FSH levels were significantly lower in the testosterone group (Table 1) . Older men and testosterone J Svartberg et al Serum PSA increased in the testosterone group and was significantly higher at the end of the study compared to the placebo group (Figure 1 ). Only three of the participants had PSA levels44.0 mg/l at the end of the study (two in the treatment group, 4.5 and 4.9 mg/l, and one in the placebo group, 4.2 mg/l). Both hematocrit and hemoglobin levels increased in the treatment group and were significantly higher compared to the placebo group at the end of the study (Figure 1) .
Compared to the placebo group, weight, BMI and WC did not change significantly during testosterone treatment. However, significant changes were seen regarding body composition. Thus, in the testosterone treatment group, the FFM increased 4.2 kg whereas the FM was reduced with 5.7%, which were significantly different, compared with the placebo group at the end of the study. Furthermore, testosterone treatment significantly reduced the SAT and TAT (Po0.001 and Po0.05, respectively) ( Table 1) .
Testosterone treatment did not increase strength in knee extension or handgrip strength. In the placebo group, the handgrip strength was reduced in both the dominant and the non-dominant hand leading to a significant difference between the groups in the dominant hand at the end of the study. There were no differences between the groups in the functional tests or in the IPAQ score. BMD in the hip increased significantly during testosterone treatment, and there was a significant difference between the groups at the end of the treatment (Table 2) .
Testosterone treatment had no effect on the glucose metabolism or the lipids (Table 3 ). There were no significant differences in any parameter on emotional function, QoL (Table 4) or cognitive function (Table 5 ) between the testosterone and the placebo group at the end of the study.
Discussion
The main finding in the case-control study was that older men with a subnormal testosterone level had an unfavorable metabolic profile and fat distribution, and that testosterone treatment mainly affected the body composition. 
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Men with subnormal testosterone levels had higher weight, WC, FM and TAT compared with men with normal testosterone levels, and the differences were large. In addition, men with subnormal testosterone levels had higher glucose and insulin levels, were more insulin resistant and had higher triglycerides. Testosterone treatment proved to have a large impact on body composition with a reduction in FM, SAT, TAT and an increase in FFM. Our findings are in agreement with previous studies in older men. [15] [16] [17] The testosterone treatment, however, had no effect on body weight, a finding also reported by the previous studies. Thus, the men in our study were still largely overweight after a year of testosterone treatment, which may be one explanation as to why testosterone treatment did not have any effect on the glucose metabolism and the lipids. Another possible explanation would be that we examined a group of men with subnormal testosterone levels during at least 4 years, and that a longer and/or earlier testosterone intervention might be necessary to normalize the metabolic profile. Lastly, it could be argued that a subnormal testosterone level in elderly men is only a surrogate measure for the metabolic syndrome. In the Kuopio Ischemic Heart Disease Risk Factor Study, men with the metabolic syndrome had a threefold increased risk of developing hypogonadism 11 years later. 18 However, the opposite relation was also described by Laaksonen et al., 19 and men with testosterone levels in the lower quartile were twofold more likely to develop the metabolic syndrome 11 years later. Thus, the metabolic syndrome may not only be a consequence of low testosterone levels but may also be a cause of hypogonadism. The metabolic syndrome is associated with an increased risk of CHD, 20 and one important indication for testosterone treatment in elderly men would be if testosterone treatment could improve the metabolic conditions, thus reducing the risk of CHD. However, in our study testosterone treatment alone did not improve the lipid profile and the insulin resistance. Future testosterone studies should preferably also include lifestyle interventions. Thus, Purnell et al. 21 showed that a 10% weight loss in older obese men through caloric restriction significantly improved not only visceral adiposity but also insulin sensitivity and dyslipidemia.
The increase in FFM was not associated with muscle strength but men who received testosterone treatment had significantly better grip strength in the dominant hand at the end of the study. This was due to a reduction in grip strength in the placebo group. Thus, testosterone treatment was able to at least maintain muscle strength. In previous studies, testosterone therapy was associated with a greater Table 3 Glucose metabolism and lipids in men with subnormal testosterone levels and the control group and at baseline and after 52 weeks in the intervention study Older men and testosterone J Svartberg et al improvement in grip strength compared with placebo, 17, 22, 23 whereas there were no differences reported in lower extremity muscle strength in most studies. 16, 17, 22, 23 Previous reports on the effect of testosterone on physical function have been inconsistent with one study reporting improvement in a composite score 23 whereas another study 16 reported no differences, in agreement with our results. The conflicting findings may be due to both the different testosterone doses used and/or the testosterone inclusion levels which differed between the studies. However, it is also possible that testosterone treatment in the elderly men may affect selective components of the muscle morphology and function. The effect of testosterone on BMD has yielded inconsistent results, but two longer trials 24, 25 showed a moderate increase in lumbar and hip BMD. The effect of testosterone on the BMD was moderate in our study also, and we found a significant difference only in the total hip. The mechanism by which testosterone improves BMD is not completely understood, but at least some of the effects are likely to be mediated by its conversion to estradiol. Aromatase deficiency has been associated with low BMD and high testosterone levels, and estradiol treatment increased BMD. 26 In our study, estradiol did not increase in the group receiving testosterone, but estradiol levels were significantly higher compared to the placebo group. Although testosterone treatment seems beneficial on bone health, no study has so far reported an effect on fracture rates.
Few placebo-controlled randomized studies in elderly men have reported on testosterone's effect on QoL and the results have been inconsistent. 27, 28 In our case-control study, we found that men with normal testosterone levels had better results in the somatic domain and in the total score of the AMS, but we found no difference in the WHO-OLD or the GHQ compared to men with subnormal testosterone levels. Thus, the differences between the groups in QoL were altogether small, including sexuality. We cannot rule out that we lack statistical power for these analyses as the men who received testosterone treatment improved their result in the sexual domain of AMS to the level of the control group in the case-control study. It is, however, interesting to note that although the men differed largely in weight, BMI and self-reported health problems, the impact of this was just barely noticeable in the three QoL questionnaires. Men with normal testosterone levels scored, however, significantly better in the BDI compared with men with subnormal testosterone levels. But there were no significant differences in BDI between the testosterone and the placebo group at the end of the intervention study. Our data are supported by previous studies showing lower testosterone levels among depressed men than in age-matched controls 29 whereas randomized trials failed to find significant effects of testosterone treatment. 30, 31 Although men with normal testosterone had more favorable results in 10 of the 12 cognitive function tests and the composite score compared to men with subnormal testosterone, the difference was only significant in one test. Testosterone treatment did not improve cognitive function in agreement with previous studies. 32 This study has strengths, such as, that we included men from a general population and that Older men and testosterone J Svartberg et al they were enrolled in the study only if they had a consistent subnormal testosterone level (or normal for the control group) 4 years after the first measurement. This, we believe ensured a good selection of the men in their respective group, and as only three men in the whole age-group sample of the fifth Tromsø sample reported use of testosterone, a selection bias is unlikely. There are also weaknesses in the study and the most important is the unfortunately low number of enrolled men. More than half the number of men with subnormal testosterone levels in 2001 were found to have normal testosterone levels 4 years later. This could be explained by regression towards the mean and probably more important to the fact that testosterone measurements in 2001 were performed between 0800 and 1800 hours and not as preferably in the morning when testosterone levels are at their highest. In addition, a large part of the men with subnormal testosterone levels had slightly increased PSA and were therefore excluded from participation in the intervention study. This gives us, on the other hand, an indication of the number of men that would need to be screened for a large testosterone trial. Nebido was well tolerated, with only a few complaints concerning soreness in the injection area. There were no complaints about fluid retention, sleep disturbances or lower urinary tract symptoms during the treatment period in either of the treatment groups. The injections ensured compliance to the study medication. A stable testosterone level in the normal range was noticed already after the second injection; however, in the majority of the men LH levels dropped below the level of detection, suggesting a need to individualize Older men and testosterone J Svartberg et al the injection intervals. In regards to safety assessment, the increase in PSA was moderate and did not require any participants to be taken off the medication, and in addition there were no urinary complaints. The hematocrit increased as expected but again not to problematic levels. In summary, we found that elderly men with subnormal testosterone had a less favorable metabolic profile and had slightly reduced QoL and emotional and cognitive function. Testosterone treatment had a large impact on body composition with reduced FM and abdominal adipose tissue and increased FFM, but it did not affect weight or improve the glucose and lipid metabolism. Thus, testosterone treatment alone is not sufficient to reverse the unfavorable metabolic profile in elderly men with subnormal testosterone.
